Armonica, a pioneer in optical epigenetic sequencing has appointed Emily Milsovic as its new chief executive officer (CEO), effective immediately. Ms. Milsovic succeeds Victor Esch, Ph.D., as part of a planned leadership transition as he retires. Ms. Milsovic will remain a member of the Armonica Board of Directors.
Milsovic is an accomplished biotech executive and brings more than two decades of relevant industry and leadership experience to her new role. Her significant expertise in globally commercializing disruptive life science technologies, diagnostics, and services is a testament to her ability to drive innovation, growth, and commercial success. Previously, Milsovic served as Vice President of Business Operations at Illumina and Chief Marketing Officer and Head of product management for llumina’s GRAIL subsidiary. Before Illumina, Milsovic held several senior positions at Danaher and Thermo Fisher Scientific.
“Victor has done a fantastic job getting to this point. Emily’s transition to CEO and the recent addition of Todd Dickinson to our Board signals the market promise of this technology. I’m thrilled that Emily has decided to step into the CEO role. Armonica has recently generated fantastic new data. Emily’s extensive global experience will lead Armonica’s transition from research to commercialization of this disruptive approach to epigenetic sequencing. Having joined Armonica’s Board earlier this year, Emily is ready to hit the ground running, and we expect a seamless transition,” said Dave Blivin, Chairman of Armonica’s board.
“I’m honored to lead the talented Armonica team,” said Milsovic. “Armonica’s new feasibility data is exciting, and we now have the potential to revolutionize how we interrogate the genome. Our method retains critical epigenetic data, which is often unseen or missing. Revealing new epigenetic data using our proprietary method will unlock the promise of molecular medicine,” said Milsovic.
